Your browser doesn't support javascript.
loading
Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis.
Sklepkiewicz, Piotr; Dymek, Barbara A; Mlacki, Michal; Koralewski, Robert; Mazur, Marzena; Nejman-Gryz, Patrycja; Korur, Serdar; Zagozdzon, Agnieszka; Rymaszewska, Aleksandra; von der Thüsen, Jan H; Siwinska, Anna M; Güner, Nazan Cemre; Cheda, Lukasz; Paplinska-Goryca, Magdalena; Proboszcz, Malgorzata; van den Bosch, Thierry P P; Górska, Katarzyna; Golab, Jakub; Kaminski, Rafal M; Krenke, Rafal; Golebiowski, Adam; Dzwonek, Karolina; Dobrzanski, Pawel.
Afiliação
  • Sklepkiewicz P; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Dymek BA; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland; Postgraduate School of Molecular Medicine, Medical University of Warsaw, 02-097, Warsaw, Poland. Electronic address: b.dymek@oncoarendi.com.
  • Mlacki M; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Koralewski R; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Mazur M; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Nejman-Gryz P; Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • Korur S; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Zagozdzon A; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Rymaszewska A; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • von der Thüsen JH; Department of Pathology, Erasmus Medical Center, 3015 GD, Rotterdam, the Netherlands.
  • Siwinska AM; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Güner NC; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Cheda L; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Paplinska-Goryca M; Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • Proboszcz M; Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • van den Bosch TPP; Department of Pathology, Erasmus Medical Center, 3015 GD, Rotterdam, the Netherlands.
  • Górska K; Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • Golab J; Department of Immunology, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • Kaminski RM; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Krenke R; Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, 02-097, Warsaw, Poland.
  • Golebiowski A; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Dzwonek K; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
  • Dobrzanski P; OncoArendi Therapeutics SA, 02-089, Warsaw, Poland.
Eur J Pharmacol ; 919: 174792, 2022 Mar 15.
Article em En | MEDLINE | ID: mdl-35122869
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Fibrose Pulmonar Idiopática / Hexosaminidases Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores de Proteínas Quinases / Fibrose Pulmonar Idiopática / Hexosaminidases Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia